cas 869365-97-9|| where to buy (5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone

Nombre del producto:(5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone

IUPAC Name:(5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone

Unidad de embalaje	Stock disponible	Precio($)
CM128905-100mg	in stock	ƴţ
CM128905-250mg	in stock	ţţǟ
CM128905-1g	in stock	řǸţ
CM128905-5g	in stock	ħƴĳ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 869365-97-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :869365-97-9; Fórmula molecular:C13H6ClF2IO; Punto de fusión:-; Código de sonrisas:FC1=CC=CC(F)=C1C(=O)C1=C(I)C=CC(Cl)=C1; Densidad:

: Número de catálogo:CM128905; Peso molecular:378.54; Punto de ebullición:433°C at 760 mmHg; Nº Mdl:MFCD10565698; Almacenamiento:Keep in dark place, store at 2-8°C.

: Alisertib; Puma Biotechnology announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1 trial will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed on or after first-line platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial is objective response rate, with secondary endpoints of duration of response, disease control rate, progression-free survival and overall survival. Based upon the outcomes of the study, Puma anticipates meeting with the FDA to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer. Alisertib is an orally active and selective Aurora A kinase inhibitor, which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.